This website is intended for healthcare professionals. If you are a member of the public, please click here

 

<font size="4.5">What is FERACCRU<sup>®</sup></font>

What is FERACCRU®

FERACCRU® is an oral treatment for iron deficiency (ID) in adults.1

 

Each capsule contains 30 mg of iron as ferric maltol1

  • FERACCRU® should be taken twice a day and swallowed whole on an empty stomach with water.
  • FERACCRU® should not be used in inflammatory bowel disease (IBD) flare or in IBD patients with haemoglobin (Hb) <9.5 g/dL.1

For further information on special warnings, precautions and contraindications, please refer to the GB SPC or NI SPC.

                                                                 For illustrative purposes only, not actual size

Key benefits of FERACCRU® from the AEGIS trials  

FERACCRU® relieved IDA in patients with IBD (without flare) by 12 weeks vs placebo in 66% of patients2

FERACCRU® was well-tolerated vs placebo2,3

FERACCRU® short-term (12 weeks) or long-term (up to 64 weeks) therapy did not lead to iron overload4

When to use FERACCRU<sup>®</sup> When to use FERACCRU®

References

  1. FERACCRU® Summary of Product Characteristics. Available for the UK from: https://www.medicines.org.uk/emc. Available for Northern Ireland from: https://www.emcmedicines.com/en-GB/northernireland/
  2. Gasche C, et al. Inflamm Bowel Dis 2015;21(3):579–588.
  3. Schmidt C, et al. Aliment Pharmacol Ther 2016;44(3):259–270.
  4. Norgine DOF 493. November 2018.
External Link

You are now leaving a Norgine website and entering a third-party website.
Norgine is not responsible for the content of external websites.

Please confirm you wish to follow this link.

Continue Cancel